Clinical trials: Transient Ischemic Attacks
Transient Ischemic Attack, Stroke
Sleep Apnea in TIA/Stroke: Reducing Cardiovascular Risk With Positive Airway Pressure
The goal of this study is to develop a novel study design to safely and ethically conduct a long-term randomized controlled trial among patients at high risk for both sleep apnea and cardiovascular events that will examine…
- Trial name
- SleepTight (NCT01446913)
- Testing
- Standard CPAP Intervention, Enhanced CPAP Intervention
- Where
- 2 sites in United States
- Volunteers
- 255 people
- Sponsor
- Yale University
Stroke, Transient Ischemic Attack
VITATOPS: A Study of VITAmins TO Prevent Stroke
The VITATOPS study is a multi-center, randomized, double blind, placebo-controlled secondary stroke prevention trial to determine whether the addition of vitamin supplements (B12 500 ug, B6 25 mg, Folate 2 mg) to best…
- Trial name
- NCT00097669
- Where
- 111 sites in United States, Australia and 18 more
- Volunteers
- 8,164 people
- Sponsor
- VITATOPS
Stroke, Ischemic Attack, Transient
Connected Health Blood Pressure Monitoring In Stroke and TIA Patients
The goal of this pilot project is to assess adherence with home blood pressure monitoring in hypertensive patients with a history of cerebral infarction and to determine if a social incentive improves adherence with monitoring.
- Trial name
- CHAMPS (NCT02450760)
- Testing
- Social incentive
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Pennsylvania
Non-valvular Atrial Fibrillation
Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation
The purpose of this study are 1) to characterize the primary and secondary prevention patients, 2) to calculate incidence rates of stroke/SE or major bleeding in each cohort and 3) to investigate for Japanese secondary prevention…
- Trial name
- NCT05321810
- Testing
- Apixaban, Warfarin
- Where
- Japan
- Volunteers
- 193,565 people
- Sponsor
- Pfizer
Stroke
Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)
This is a study in patients who recently had a brain attack (stroke) and in whom no clear cause of the stroke could be identified.
- Trial name
- NAVIGATE ESUS (NCT02313909)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic acid (Aspirin, BAY1019036)
- Where
- 454 sites in United States, Argentina and 29 more
- Volunteers
- 7,213 people
- Sponsor
- Bayer